The primary objective of this study is to evaluate the effect of 12 weeks of treatment with
once daily administration of AQX-1125 compared to placebo in subjects following exacerbations
of Chronic Obstructive Pulmonary Disease (COPD) by targeting the SHIP1 (Src Homology
2-containing Inositol-5'-Phosphatase 1) pathway.